In a real-world setting, tofacitinib and baricitinib have comparable continuing efficacies and safety profiles in patients with RA.It is important to determine the differences and similarities of JAK inhibitors in a real-world setting so that the optimal agent can be administered. However, until now, no published data of a direct comparison among these agents in RA have been available. With this in mind, Iwamoto, et al. compared the efficacy and safety of tofacitinib with those of baricitinib by comparing multiple variable-adjusted estimates in a real-world setting.

Keywords:


Publication thumbnail: 関節リウマチ患者の実臨床におけるトファシチニブとバリシチニブの有効性および安全性の比較
LinkedIn